[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f1mgtj70MyGGW1fleO6ijYm7Kmd2uFbRPw2RqjJmUcsg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":71,"rows":78},"University of Roma La Sapienza",[4],386,false,38,22,100045,8,285,[14,17,20,22,25,28,30,33],{"name":15,"count":16},"Coronary Artery Disease",25,{"name":18,"count":19},"Obesity",17,{"name":21,"count":11},"Septic Shock",{"name":23,"count":24},"Bariatric Surgery Candidate",6,{"name":26,"count":27},"Wound Heal",5,{"name":29,"count":27},"Pain",{"name":31,"count":32},"Fibromyalgia",4,{"name":34,"count":32},"Cirrhosis",[36,41,46,51,56,61,66],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06738342","Clinical Efficacy of a Chlorhexidine-based Mouth-rinse Containing Citrus Aurantium Amara","2025-03","CHX 0.12%",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06720805","Pentabiocel in Pediatric IBS","2025-07-31","Pentabiocel",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04464122","Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)","2025-09-14","Somatostatin analog; chemotherapy",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06198673","A Prospective muLticEnter Registry in chrONic coronARy synDrOme","2025-12-31","Antiplatelet Agents",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07305519","The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin D in Preventing Preterm Birth:","2027-04-01","Magnesium-PEA-HMW Hyaluronic Acid-Vitamin B6-Vitamin D + Vaginal Progesterone",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07485023","Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation","2028-07-01","Oral iron supplementation",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05962541","Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)","2028-12","PDD-TURBT with hexaminolevulinate",[72,73,74,75,76,77],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[79,106,129,151,172,195,213,235,260,315,358,407,445,482,510,545,575,607,648,673,698,716,738,756,782,800,826,844,867,890,916,938,966,984,1002,1020,1045,1072,1090,1114,1132,1159,1177,1195,1220,1238,1263,1292,1316,1334,1352,1377,1404,1422,1440,1462,1480,1498,1521,1539,1564,1590,1613,1639,1657,1680,1705,1723,1750,1768,1786,1804,1822,1847,1872,1890,1908,1935,1953,1971,1995,2013,2039,2057,2075,2093,2111,2135,2153,2179,2197,2222,2254,2282,2300,2325,2343,2369,2387,2405,2431,2484,2517,2550,2575,2593,2620,2644,2670,2695,2720,2744,2768,2786,2813,2836,2861,2879,2902,2928,2946,2970,2988,3014,3032,3054,3077,3095,3118,3144],{"intervention":70,"totalTrials":80,"cells":81},1,{"EARLY_PHASE1":82,"PHASE1":85,"PHASE2":87,"PHASE3":89,"PHASE4":91,"NA":104},{"trials":83,"activeCount":84},[],0,{"trials":86,"activeCount":84},[],{"trials":88,"activeCount":84},[],{"trials":90,"activeCount":84},[],{"trials":92,"activeCount":80,"soonestReadout":69},[93],{"nctId":67,"briefTitle":68,"status":94,"phases":95,"primaryCompletion":69,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":103},"RECRUITING",[76],"2031-12","2025-12-22",327,[100,101,102],"Non-muscle-invasive Bladder Cancer","Non-Muscle Invasive Bladder Urothelial Carcinoma","High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma",[70],{"trials":105,"activeCount":84},[],{"intervention":40,"totalTrials":80,"cells":107},{"EARLY_PHASE1":108,"PHASE1":110,"PHASE2":112,"PHASE3":114,"PHASE4":116,"NA":118},{"trials":109,"activeCount":84},[],{"trials":111,"activeCount":84},[],{"trials":113,"activeCount":84},[],{"trials":115,"activeCount":84},[],{"trials":117,"activeCount":84},[],{"trials":119,"activeCount":80,"soonestReadout":39},[120],{"nctId":37,"briefTitle":38,"status":121,"phases":122,"primaryCompletion":39,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"NOT_YET_RECRUITING",[77],"2025-04","2024-12",32,[127],"Wound Healing",[40],{"intervention":45,"totalTrials":80,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":141},{"trials":132,"activeCount":84},[],{"trials":134,"activeCount":84},[],{"trials":136,"activeCount":84},[],{"trials":138,"activeCount":84},[],{"trials":140,"activeCount":84},[],{"trials":142,"activeCount":80,"soonestReadout":44},[143],{"nctId":42,"briefTitle":43,"status":121,"phases":144,"primaryCompletion":44,"completion":54,"start":145,"enrollment":146,"conditions":147,"interventions":150},[77],"2024-12-01",56,[148,149],"Irritable Bowel Syndrome (IBS)","Pediatrics",[45],{"intervention":55,"totalTrials":80,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":163},{"trials":154,"activeCount":84},[],{"trials":156,"activeCount":84},[],{"trials":158,"activeCount":84},[],{"trials":160,"activeCount":84},[],{"trials":162,"activeCount":84},[],{"trials":164,"activeCount":80,"soonestReadout":54},[165],{"nctId":52,"briefTitle":53,"status":121,"phases":166,"primaryCompletion":54,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":171},[],"2026-12-31","2024-01-01",1000,[15],[55],{"intervention":65,"totalTrials":80,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":184},{"trials":175,"activeCount":84},[],{"trials":177,"activeCount":84},[],{"trials":179,"activeCount":84},[],{"trials":181,"activeCount":84},[],{"trials":183,"activeCount":84},[],{"trials":185,"activeCount":80,"soonestReadout":64},[186],{"nctId":62,"briefTitle":63,"status":121,"phases":187,"primaryCompletion":64,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},[77],"2028-09-01","2026-07-01",128,[192],"Anemia Complicating Pregnancy",[65,194],"IV iron administration",{"intervention":194,"totalTrials":80,"cells":196},{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":207},{"trials":198,"activeCount":84},[],{"trials":200,"activeCount":84},[],{"trials":202,"activeCount":84},[],{"trials":204,"activeCount":84},[],{"trials":206,"activeCount":84},[],{"trials":208,"activeCount":80,"soonestReadout":64},[209],{"nctId":62,"briefTitle":63,"status":121,"phases":210,"primaryCompletion":64,"completion":188,"start":189,"enrollment":190,"conditions":211,"interventions":212},[77],[192],[65,194],{"intervention":60,"totalTrials":80,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":225},{"trials":216,"activeCount":84},[],{"trials":218,"activeCount":84},[],{"trials":220,"activeCount":84},[],{"trials":222,"activeCount":84},[],{"trials":224,"activeCount":84},[],{"trials":226,"activeCount":80,"soonestReadout":59},[227],{"nctId":57,"briefTitle":58,"status":94,"phases":228,"primaryCompletion":59,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},[77],"2028-01-01","2026-04-01",150,[233],"Preterm Labor",[60],{"intervention":50,"totalTrials":80,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":247},{"trials":238,"activeCount":84},[],{"trials":240,"activeCount":84},[],{"trials":242,"activeCount":84},[],{"trials":244,"activeCount":84},[],{"trials":246,"activeCount":84},[],{"trials":248,"activeCount":80,"soonestReadout":49},[249],{"nctId":47,"briefTitle":48,"status":94,"phases":250,"primaryCompletion":49,"completion":54,"start":251,"enrollment":252,"conditions":253,"interventions":259},[],"2020-09-14",60,[254,255,256,257,258],"Neuroendocrine Tumors","Neuroendocrine Neoplasm","Neuroendocrine Tumor Grade 1","Neuroendocrine Tumor Grade 2","Neuroendocrine Carcinoma",[50],{"intervention":261,"totalTrials":32,"cells":262},"Atorvastatin",{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":313},{"trials":264,"activeCount":84},[],{"trials":266,"activeCount":84},[],{"trials":268,"activeCount":84},[],{"trials":270,"activeCount":84},[],{"trials":272,"activeCount":84},[273,285,295,304],{"nctId":274,"briefTitle":275,"status":276,"phases":277,"primaryCompletion":278,"completion":279,"start":280,"enrollment":252,"conditions":281,"interventions":284},"NCT01322711","Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes","UNKNOWN",[76],"2015-10","2015-12","2011-03",[282,283],"Type 2 Diabetes Mellitus","Hypercholesterolemia",[261],{"nctId":286,"briefTitle":287,"status":276,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":231,"conditions":292,"interventions":293},"NCT02030054","Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)",[76],"2015-06","2015-09","2015-01",[15],[261,294],"Rosuvastatin",{"nctId":296,"briefTitle":297,"status":276,"phases":298,"primaryCompletion":299,"completion":289,"start":300,"enrollment":301,"conditions":302,"interventions":303},"NCT01567774","Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity",[76],"2014-03","2012-04",100,[15],[261,294],{"nctId":305,"briefTitle":306,"status":276,"phases":307,"primaryCompletion":279,"completion":308,"start":309,"enrollment":301,"conditions":310,"interventions":311},"NCT01648829","PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity",[76],"2017-12","2014-01",[15],[261,312],"Pitavastatin",{"trials":314,"activeCount":84},[],{"intervention":294,"totalTrials":32,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":323,"PHASE4":337,"NA":356},{"trials":318,"activeCount":84},[],{"trials":320,"activeCount":84},[],{"trials":322,"activeCount":84},[],{"trials":324,"activeCount":84},[325],{"nctId":326,"briefTitle":327,"status":328,"phases":329,"primaryCompletion":330,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":335},"NCT01007279","Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)","COMPLETED",[75],"2010-09","2010-03",160,[334],"Periprocedural Myocardial Necrosis",[336],"ROSUVASTATIN",{"trials":338,"activeCount":84},[339,348,352],{"nctId":340,"briefTitle":341,"status":276,"phases":342,"primaryCompletion":343,"completion":308,"start":309,"enrollment":344,"conditions":345,"interventions":347},"NCT01899027","Rosuvastatin for Preventing Complications in Renal Ablation",[76],"2016-12",112,[346],"Arterial Hypertension",[294],{"nctId":286,"briefTitle":287,"status":276,"phases":349,"primaryCompletion":289,"completion":290,"start":291,"enrollment":231,"conditions":350,"interventions":351},[76],[15],[261,294],{"nctId":296,"briefTitle":297,"status":276,"phases":353,"primaryCompletion":299,"completion":289,"start":300,"enrollment":301,"conditions":354,"interventions":355},[76],[15],[261,294],{"trials":357,"activeCount":84},[],{"intervention":359,"totalTrials":360,"cells":361},"Clopidogrel",3,{"EARLY_PHASE1":362,"PHASE1":364,"PHASE2":366,"PHASE3":368,"PHASE4":392,"NA":405},{"trials":363,"activeCount":84},[],{"trials":365,"activeCount":84},[],{"trials":367,"activeCount":84},[],{"trials":369,"activeCount":84},[370,381],{"nctId":371,"briefTitle":372,"status":276,"phases":373,"primaryCompletion":374,"completion":374,"start":375,"enrollment":252,"conditions":376,"interventions":379},"NCT00751491","Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI)",[75],"2009-09","2008-09",[377,378],"Stable Angina","Percutaneous Coronary Intervention",[380,359],"Adenosin",{"nctId":382,"briefTitle":383,"status":328,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT01543932","High Clopidogrel Dose Versus Prasugrel and Ticagrelor in High Reactive Stable Patients",[75],"2013-12","2012-07",81,[15],[359,390,391],"Prasugrel","Ticagrelor",{"trials":393,"activeCount":84},[394],{"nctId":395,"briefTitle":396,"status":276,"phases":397,"primaryCompletion":398,"completion":399,"start":386,"enrollment":400,"conditions":401,"interventions":403},"NCT01627431","Residual Platelet Activity In Advanced Peripheral Artery Disease",[76],"2014-07","2015-07",410,[402],"Peripheral Arterial Disease",[404,359],"Acetylsalicylic acid",{"trials":406,"activeCount":84},[],{"intervention":408,"totalTrials":360,"cells":409},"Ranolazine",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":443},{"trials":411,"activeCount":84},[],{"trials":413,"activeCount":84},[],{"trials":415,"activeCount":84},[],{"trials":417,"activeCount":84},[],{"trials":419,"activeCount":84},[420,428,437],{"nctId":421,"briefTitle":422,"status":276,"phases":423,"primaryCompletion":424,"completion":343,"start":309,"enrollment":301,"conditions":425,"interventions":427},"NCT01495520","Ranolazine for Improving Symptoms of Palpitations",[76],"2014-12",[426],"Ischemic Heart Disease",[408],{"nctId":429,"briefTitle":430,"status":276,"phases":431,"primaryCompletion":432,"completion":432,"start":433,"enrollment":301,"conditions":434,"interventions":435},"NCT01490255","Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity",[76],"2014-06","2012-01",[15],[408,436],"Amlodipine",{"nctId":438,"briefTitle":439,"status":276,"phases":440,"primaryCompletion":279,"completion":308,"start":309,"enrollment":301,"conditions":441,"interventions":442},"NCT01491061","Ranolazine Loading to Prevent PCI-induced Myocardial Injury",[76],[15],[408],{"trials":444,"activeCount":84},[],{"intervention":446,"totalTrials":447,"cells":448},"Levosimendan",2,{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":466,"PHASE4":468,"NA":480},{"trials":450,"activeCount":84},[],{"trials":452,"activeCount":84},[],{"trials":454,"activeCount":84},[455],{"nctId":456,"briefTitle":457,"status":328,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":464},"NCT00800306","Effects of Levosimendan on Microcirculation in Septic Shock",[74],"2008-02","2009-04","2007-11",40,[21],[446,465],"dobutamine",{"trials":467,"activeCount":84},[],{"trials":469,"activeCount":84},[470],{"nctId":471,"briefTitle":472,"status":328,"phases":473,"primaryCompletion":474,"completion":474,"start":475,"enrollment":301,"conditions":476,"interventions":478},"NCT00610350","Levosimendan and Myocardial Protection",[76],"2007-02","2005-01",[477],"Myocardial Protection",[479],"levosimendan",{"trials":481,"activeCount":84},[],{"intervention":483,"totalTrials":447,"cells":484},"Thalidomide",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":508},{"trials":486,"activeCount":84},[],{"trials":488,"activeCount":84},[],{"trials":490,"activeCount":84},[],{"trials":492,"activeCount":84},[],{"trials":494,"activeCount":84},[495,501],{"nctId":496,"briefTitle":497,"status":276,"phases":498,"primaryCompletion":289,"completion":308,"start":309,"enrollment":301,"conditions":499,"interventions":500},"NCT01638078","Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation",[76],[15],[483],{"nctId":502,"briefTitle":503,"status":276,"phases":504,"primaryCompletion":385,"completion":424,"start":386,"enrollment":301,"conditions":505,"interventions":507},"NCT01640639","THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure",[76],[506],"Congestive Heart Failure",[483],{"trials":509,"activeCount":84},[],{"intervention":511,"totalTrials":447,"cells":512},"Tadalafil",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":543},{"trials":514,"activeCount":84},[],{"trials":516,"activeCount":84},[],{"trials":518,"activeCount":84},[],{"trials":520,"activeCount":84},[],{"trials":522,"activeCount":84},[523,535],{"nctId":524,"briefTitle":525,"status":328,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":534},"NCT01803828","REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs",[76],"2019-01","2019-07","2014-05",120,[532,533],"Diabetic Cardiomyopathy","Diabetes Mellitus Type 2",[511],{"nctId":536,"briefTitle":537,"status":328,"phases":538,"primaryCompletion":289,"completion":290,"start":291,"enrollment":539,"conditions":540,"interventions":542},"NCT02554045","Daily Tadalafil on Body Fat and Lean Mass",[76],20,[18,541],"Sexual Dysfunction",[511],{"trials":544,"activeCount":84},[],{"intervention":546,"totalTrials":447,"cells":547},"Ezetimibe",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":556,"NA":573},{"trials":549,"activeCount":84},[],{"trials":551,"activeCount":84},[],{"trials":553,"activeCount":84},[],{"trials":555,"activeCount":84},[],{"trials":557,"activeCount":84},[558,565],{"nctId":559,"briefTitle":560,"status":276,"phases":561,"primaryCompletion":279,"completion":308,"start":309,"enrollment":562,"conditions":563,"interventions":564},"NCT01807078","Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients",[76],200,[15],[546],{"nctId":566,"briefTitle":567,"status":276,"phases":568,"primaryCompletion":424,"completion":343,"start":569,"enrollment":301,"conditions":570,"interventions":571},"NCT01490229","Ezetimibe Versus Nutraceuticals in Statin-intolerant Patients",[76],"2013-01",[15],[546,572],"Nutraceuticals",{"trials":574,"activeCount":84},[],{"intervention":576,"totalTrials":447,"cells":577},"Tripliam",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":586,"NA":605},{"trials":579,"activeCount":84},[],{"trials":581,"activeCount":84},[],{"trials":583,"activeCount":84},[],{"trials":585,"activeCount":84},[],{"trials":587,"activeCount":84},[588,598],{"nctId":589,"briefTitle":590,"status":276,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":301,"conditions":595,"interventions":596},"NCT02710539","Once-daily Fixed Combination of Three Antihypertensive Drugs",[76],"2019-03","2020-03","2016-04",[346],[597,576],"perindopril, indapamide , amlodipine",{"nctId":599,"briefTitle":600,"status":276,"phases":601,"primaryCompletion":592,"completion":593,"start":594,"enrollment":301,"conditions":602,"interventions":603},"NCT02710552","Low-dose Combination of Three Antihypertensive Drugs",[76],[346],[576,604],"Reaptan",{"trials":606,"activeCount":84},[],{"intervention":608,"totalTrials":447,"cells":609},"Testosterone undecanoate",{"EARLY_PHASE1":610,"PHASE1":612,"PHASE2":614,"PHASE3":616,"PHASE4":632,"NA":646},{"trials":611,"activeCount":84},[],{"trials":613,"activeCount":84},[],{"trials":615,"activeCount":84},[],{"trials":617,"activeCount":84},[618],{"nctId":619,"briefTitle":620,"status":328,"phases":621,"primaryCompletion":622,"completion":623,"start":624,"enrollment":146,"conditions":625,"interventions":630},"NCT01206270","Androgen for Leydig Cell Proliferation",[74,75],"2017-06","2018-06","2009-06",[626,627,628,629],"Klinefelter Syndrome","Hypergonadotropic Hypogonadism","Hypergonadotropic Azospermia","Hypergonadotropic Cryptozoospermia",[608,631],"Castor Oil",{"trials":633,"activeCount":84},[634],{"nctId":635,"briefTitle":636,"status":328,"phases":637,"primaryCompletion":638,"completion":638,"start":639,"enrollment":640,"conditions":641,"interventions":644},"NCT03126656","Effects of Testosterone on Myocardial Repolarization",[76],"2017-04","2016-09",123,[642,643],"Hypogonadism","Chronic Heart Failure",[645],"Testosterone Undecanoate",{"trials":647,"activeCount":84},[],{"intervention":572,"totalTrials":447,"cells":649},{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":671},{"trials":651,"activeCount":84},[],{"trials":653,"activeCount":84},[],{"trials":655,"activeCount":84},[],{"trials":657,"activeCount":84},[],{"trials":659,"activeCount":84},[660,667],{"nctId":661,"briefTitle":662,"status":276,"phases":663,"primaryCompletion":279,"completion":308,"start":309,"enrollment":301,"conditions":664,"interventions":666},"NCT01649986","Nutraceuticals to Improve Lipid Profile in European Countries",[76],[665],"Hyperlipidemia",[572],{"nctId":566,"briefTitle":567,"status":276,"phases":668,"primaryCompletion":424,"completion":343,"start":569,"enrollment":301,"conditions":669,"interventions":670},[76],[15],[546,572],{"trials":672,"activeCount":84},[],{"intervention":674,"totalTrials":80,"cells":675},"Regular-insulin",{"EARLY_PHASE1":676,"PHASE1":678,"PHASE2":680,"PHASE3":682,"PHASE4":684,"NA":696},{"trials":677,"activeCount":84},[],{"trials":679,"activeCount":84},[],{"trials":681,"activeCount":84},[],{"trials":683,"activeCount":84},[],{"trials":685,"activeCount":84},[686],{"nctId":687,"briefTitle":688,"status":328,"phases":689,"primaryCompletion":299,"completion":529,"start":690,"enrollment":691,"conditions":692,"interventions":694},"NCT02165566","Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit",[76],"2013-03",28,[693],"Hyperglycemia",[674,695],"Lispro-insulin",{"trials":697,"activeCount":84},[],{"intervention":695,"totalTrials":80,"cells":699},{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":708,"NA":714},{"trials":701,"activeCount":84},[],{"trials":703,"activeCount":84},[],{"trials":705,"activeCount":84},[],{"trials":707,"activeCount":84},[],{"trials":709,"activeCount":84},[710],{"nctId":687,"briefTitle":688,"status":328,"phases":711,"primaryCompletion":299,"completion":529,"start":690,"enrollment":691,"conditions":712,"interventions":713},[76],[693],[674,695],{"trials":715,"activeCount":84},[],{"intervention":717,"totalTrials":80,"cells":718},"Intensive treatment with sodium bicarbonate",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":736},{"trials":720,"activeCount":84},[],{"trials":722,"activeCount":84},[],{"trials":724,"activeCount":84},[],{"trials":726,"activeCount":84},[],{"trials":728,"activeCount":84},[729],{"nctId":730,"briefTitle":731,"status":276,"phases":732,"primaryCompletion":279,"completion":308,"start":309,"enrollment":301,"conditions":733,"interventions":734},"NCT01491243","N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy",[76],[15],[717,735],"Standard treatment with saline",{"trials":737,"activeCount":84},[],{"intervention":735,"totalTrials":80,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":754},{"trials":741,"activeCount":84},[],{"trials":743,"activeCount":84},[],{"trials":745,"activeCount":84},[],{"trials":747,"activeCount":84},[],{"trials":749,"activeCount":84},[750],{"nctId":730,"briefTitle":731,"status":276,"phases":751,"primaryCompletion":279,"completion":308,"start":309,"enrollment":301,"conditions":752,"interventions":753},[76],[15],[717,735],{"trials":755,"activeCount":84},[],{"intervention":757,"totalTrials":80,"cells":758},"Plenadren",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":780},{"trials":760,"activeCount":84},[],{"trials":762,"activeCount":84},[],{"trials":764,"activeCount":84},[],{"trials":766,"activeCount":84},[],{"trials":768,"activeCount":84},[769],{"nctId":770,"briefTitle":771,"status":328,"phases":772,"primaryCompletion":773,"completion":773,"start":299,"enrollment":774,"conditions":775,"interventions":778},"NCT02277587","Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)",[76],"2016-06",89,[776,777],"Primary Adrenal Insufficiency","Secondary Adrenal Insufficiency",[757,779],"Conventional glucocorticoid therapy",{"trials":781,"activeCount":84},[],{"intervention":779,"totalTrials":80,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":798},{"trials":785,"activeCount":84},[],{"trials":787,"activeCount":84},[],{"trials":789,"activeCount":84},[],{"trials":791,"activeCount":84},[],{"trials":793,"activeCount":84},[794],{"nctId":770,"briefTitle":771,"status":328,"phases":795,"primaryCompletion":773,"completion":773,"start":299,"enrollment":774,"conditions":796,"interventions":797},[76],[776,777],[757,779],{"trials":799,"activeCount":84},[],{"intervention":801,"totalTrials":80,"cells":802},"Amelogenin",{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":807,"PHASE3":809,"PHASE4":811,"NA":824},{"trials":804,"activeCount":84},[],{"trials":806,"activeCount":84},[],{"trials":808,"activeCount":84},[],{"trials":810,"activeCount":84},[],{"trials":812,"activeCount":84},[813],{"nctId":814,"briefTitle":815,"status":328,"phases":816,"primaryCompletion":817,"completion":817,"start":818,"enrollment":27,"conditions":819,"interventions":822},"NCT04314726","Verify if Amelogenins Had Some Benefits in Improving Lower 2nd Molar Periodontal Healing After 3rd Molar Extraction",[76],"2018-04-20","2016-03-24",[820,821],"Attachment Loss, Periodontal","Teeth, Impacted",[801,823],"Placebos",{"trials":825,"activeCount":84},[],{"intervention":823,"totalTrials":80,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":836,"NA":842},{"trials":829,"activeCount":84},[],{"trials":831,"activeCount":84},[],{"trials":833,"activeCount":84},[],{"trials":835,"activeCount":84},[],{"trials":837,"activeCount":84},[838],{"nctId":814,"briefTitle":815,"status":328,"phases":839,"primaryCompletion":817,"completion":817,"start":818,"enrollment":27,"conditions":840,"interventions":841},[76],[820,821],[801,823],{"trials":843,"activeCount":84},[],{"intervention":845,"totalTrials":80,"cells":846},"anaesthetics: sevofluorane",{"EARLY_PHASE1":847,"PHASE1":849,"PHASE2":851,"PHASE3":853,"PHASE4":855,"NA":865},{"trials":848,"activeCount":84},[],{"trials":850,"activeCount":84},[],{"trials":852,"activeCount":84},[],{"trials":854,"activeCount":84},[],{"trials":856,"activeCount":84},[857],{"nctId":858,"briefTitle":859,"status":276,"phases":860,"primaryCompletion":331,"start":460,"enrollment":861,"conditions":862,"interventions":864},"NCT01052337","Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy",[76],116,[863],"Spinal Cord Diseases",[845],{"trials":866,"activeCount":84},[],{"intervention":868,"totalTrials":80,"cells":869},"Albumin",{"EARLY_PHASE1":870,"PHASE1":872,"PHASE2":874,"PHASE3":876,"PHASE4":878,"NA":888},{"trials":871,"activeCount":84},[],{"trials":873,"activeCount":84},[],{"trials":875,"activeCount":84},[],{"trials":877,"activeCount":84},[],{"trials":879,"activeCount":84},[880],{"nctId":881,"briefTitle":882,"status":328,"phases":883,"primaryCompletion":385,"completion":385,"start":884,"enrollment":539,"conditions":885,"interventions":887},"NCT01559519","Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy",[76],"2012-09",[886],"Hepatic Encephalopathy",[868],{"trials":889,"activeCount":84},[],{"intervention":891,"totalTrials":80,"cells":892},"Insulin",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":914},{"trials":894,"activeCount":84},[],{"trials":896,"activeCount":84},[],{"trials":898,"activeCount":84},[],{"trials":900,"activeCount":84},[],{"trials":902,"activeCount":84},[903],{"nctId":904,"briefTitle":905,"status":276,"phases":906,"start":907,"enrollment":908,"conditions":909,"interventions":913},"NCT00505505","Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy",[76],"2002-01",800,[910,911,912],"Subarachnoid Hemorrhage","Traumatic Brain Injury","Intracranial Hemorrhage",[891],{"trials":915,"activeCount":84},[],{"intervention":917,"totalTrials":80,"cells":918},"Association low-dose statin and nutraceuticals",{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":925,"PHASE4":927,"NA":936},{"trials":920,"activeCount":84},[],{"trials":922,"activeCount":84},[],{"trials":924,"activeCount":84},[],{"trials":926,"activeCount":84},[],{"trials":928,"activeCount":84},[929],{"nctId":930,"briefTitle":931,"status":276,"phases":932,"primaryCompletion":424,"completion":279,"start":933,"enrollment":301,"conditions":934,"interventions":935},"NCT02001883","Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients",[76],"2013-11",[15],[917],{"trials":937,"activeCount":84},[],{"intervention":939,"totalTrials":80,"cells":940},"Imipenem",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":964},{"trials":942,"activeCount":84},[],{"trials":944,"activeCount":84},[],{"trials":946,"activeCount":84},[],{"trials":948,"activeCount":84},[],{"trials":950,"activeCount":84},[951],{"nctId":952,"briefTitle":953,"status":276,"phases":954,"primaryCompletion":955,"completion":289,"start":956,"enrollment":957,"conditions":958,"interventions":959},"NCT01820026","Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis",[76],"2015-05","2012-12",96,[34],[939,960,961,962,963],"Vancomycin","azithromycin","Cefotaxime","Amoxicillin",{"trials":965,"activeCount":84},[],{"intervention":960,"totalTrials":80,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":976,"NA":982},{"trials":969,"activeCount":84},[],{"trials":971,"activeCount":84},[],{"trials":973,"activeCount":84},[],{"trials":975,"activeCount":84},[],{"trials":977,"activeCount":84},[978],{"nctId":952,"briefTitle":953,"status":276,"phases":979,"primaryCompletion":955,"completion":289,"start":956,"enrollment":957,"conditions":980,"interventions":981},[76],[34],[939,960,961,962,963],{"trials":983,"activeCount":84},[],{"intervention":962,"totalTrials":80,"cells":985},{"EARLY_PHASE1":986,"PHASE1":988,"PHASE2":990,"PHASE3":992,"PHASE4":994,"NA":1000},{"trials":987,"activeCount":84},[],{"trials":989,"activeCount":84},[],{"trials":991,"activeCount":84},[],{"trials":993,"activeCount":84},[],{"trials":995,"activeCount":84},[996],{"nctId":952,"briefTitle":953,"status":276,"phases":997,"primaryCompletion":955,"completion":289,"start":956,"enrollment":957,"conditions":998,"interventions":999},[76],[34],[939,960,961,962,963],{"trials":1001,"activeCount":84},[],{"intervention":963,"totalTrials":80,"cells":1003},{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1010,"PHASE4":1012,"NA":1018},{"trials":1005,"activeCount":84},[],{"trials":1007,"activeCount":84},[],{"trials":1009,"activeCount":84},[],{"trials":1011,"activeCount":84},[],{"trials":1013,"activeCount":84},[1014],{"nctId":952,"briefTitle":953,"status":276,"phases":1015,"primaryCompletion":955,"completion":289,"start":956,"enrollment":957,"conditions":1016,"interventions":1017},[76],[34],[939,960,961,962,963],{"trials":1019,"activeCount":84},[],{"intervention":1021,"totalTrials":80,"cells":1022},"ribavirin pre-treatment",{"EARLY_PHASE1":1023,"PHASE1":1025,"PHASE2":1027,"PHASE3":1029,"PHASE4":1031,"NA":1043},{"trials":1024,"activeCount":84},[],{"trials":1026,"activeCount":84},[],{"trials":1028,"activeCount":84},[],{"trials":1030,"activeCount":84},[],{"trials":1032,"activeCount":84},[1033],{"nctId":1034,"briefTitle":1035,"status":328,"phases":1036,"primaryCompletion":1037,"completion":1038,"start":1039,"enrollment":301,"conditions":1040,"interventions":1042},"NCT00993122","Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients",[76],"2010-04","2012-02","2009-10",[1041],"Hepatitis C",[1021],{"trials":1044,"activeCount":84},[],{"intervention":1046,"totalTrials":80,"cells":1047},"Levosimendan in addition to standard therapy",{"EARLY_PHASE1":1048,"PHASE1":1050,"PHASE2":1052,"PHASE3":1054,"PHASE4":1056,"NA":1070},{"trials":1049,"activeCount":84},[],{"trials":1051,"activeCount":84},[],{"trials":1053,"activeCount":84},[],{"trials":1055,"activeCount":84},[],{"trials":1057,"activeCount":84},[1058],{"nctId":1059,"briefTitle":1060,"status":276,"phases":1061,"completion":1062,"start":1063,"enrollment":1064,"conditions":1065,"interventions":1068},"NCT00527059","Renal Effects of Levosimendan in Patients Admitted With Acute Decompensated Heart Failure",[76],"2008-03","2007-10",21,[1066,1067],"Heart Failure","Renal Insufficiency",[1046,1069],"spironolactone, beta-blockers,ecc",{"trials":1071,"activeCount":84},[],{"intervention":1069,"totalTrials":80,"cells":1073},{"EARLY_PHASE1":1074,"PHASE1":1076,"PHASE2":1078,"PHASE3":1080,"PHASE4":1082,"NA":1088},{"trials":1075,"activeCount":84},[],{"trials":1077,"activeCount":84},[],{"trials":1079,"activeCount":84},[],{"trials":1081,"activeCount":84},[],{"trials":1083,"activeCount":84},[1084],{"nctId":1059,"briefTitle":1060,"status":276,"phases":1085,"completion":1062,"start":1063,"enrollment":1064,"conditions":1086,"interventions":1087},[76],[1066,1067],[1046,1069],{"trials":1089,"activeCount":84},[],{"intervention":1091,"totalTrials":80,"cells":1092},"Pantoprazole,",{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1112},{"trials":1094,"activeCount":84},[],{"trials":1096,"activeCount":84},[],{"trials":1098,"activeCount":84},[],{"trials":1100,"activeCount":84},[],{"trials":1102,"activeCount":84},[1103],{"nctId":1104,"briefTitle":1105,"status":276,"phases":1106,"primaryCompletion":1107,"completion":594,"start":1108,"enrollment":231,"conditions":1109,"interventions":1110},"NCT02028234","\"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors\" -Trial dOPPLER-",[76],"2015-03","2014-02",[15],[1091,1111],"Omeprazole",{"trials":1113,"activeCount":84},[],{"intervention":1111,"totalTrials":80,"cells":1115},{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1130},{"trials":1117,"activeCount":84},[],{"trials":1119,"activeCount":84},[],{"trials":1121,"activeCount":84},[],{"trials":1123,"activeCount":84},[],{"trials":1125,"activeCount":84},[1126],{"nctId":1104,"briefTitle":1105,"status":276,"phases":1127,"primaryCompletion":1107,"completion":594,"start":1108,"enrollment":231,"conditions":1128,"interventions":1129},[76],[15],[1091,1111],{"trials":1131,"activeCount":84},[],{"intervention":1133,"totalTrials":80,"cells":1134},"flavonoid-based supplements",{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1141,"PHASE4":1143,"NA":1157},{"trials":1136,"activeCount":84},[],{"trials":1138,"activeCount":84},[],{"trials":1140,"activeCount":84},[],{"trials":1142,"activeCount":84},[],{"trials":1144,"activeCount":84},[1145],{"nctId":1146,"briefTitle":1147,"status":276,"phases":1148,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":1153,"interventions":1155},"NCT03569930","Irritation and Anal Bleeding in Patients Affected by Hemorrhoids.",[76],"2018-12-01","2019-05-01","2018-05-01",105,[1154],"Hemorrhoids",[1133,1156],"Centella Complex",{"trials":1158,"activeCount":84},[],{"intervention":1156,"totalTrials":80,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1169,"NA":1175},{"trials":1162,"activeCount":84},[],{"trials":1164,"activeCount":84},[],{"trials":1166,"activeCount":84},[],{"trials":1168,"activeCount":84},[],{"trials":1170,"activeCount":84},[1171],{"nctId":1146,"briefTitle":1147,"status":276,"phases":1172,"primaryCompletion":1149,"completion":1150,"start":1151,"enrollment":1152,"conditions":1173,"interventions":1174},[76],[1154],[1133,1156],{"trials":1176,"activeCount":84},[],{"intervention":404,"totalTrials":80,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1193},{"trials":1180,"activeCount":84},[],{"trials":1182,"activeCount":84},[],{"trials":1184,"activeCount":84},[],{"trials":1186,"activeCount":84},[],{"trials":1188,"activeCount":84},[1189],{"nctId":395,"briefTitle":396,"status":276,"phases":1190,"primaryCompletion":398,"completion":399,"start":386,"enrollment":400,"conditions":1191,"interventions":1192},[76],[402],[404,359],{"trials":1194,"activeCount":84},[],{"intervention":1196,"totalTrials":80,"cells":1197},"statin + ezetimibe",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1218},{"trials":1199,"activeCount":84},[],{"trials":1201,"activeCount":84},[],{"trials":1203,"activeCount":84},[],{"trials":1205,"activeCount":84},[],{"trials":1207,"activeCount":84},[1208],{"nctId":1209,"briefTitle":1210,"status":276,"phases":1211,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":301,"conditions":1215,"interventions":1216},"NCT03277079","Low Dose Statins, Ezetimibe and Nutraceuticals",[76],"2017-12-31","2018-03-31","2017-10-01",[15],[1196,1217],"statin + ezetimibe + Nutraceuticals",{"trials":1219,"activeCount":84},[],{"intervention":1217,"totalTrials":80,"cells":1221},{"EARLY_PHASE1":1222,"PHASE1":1224,"PHASE2":1226,"PHASE3":1228,"PHASE4":1230,"NA":1236},{"trials":1223,"activeCount":84},[],{"trials":1225,"activeCount":84},[],{"trials":1227,"activeCount":84},[],{"trials":1229,"activeCount":84},[],{"trials":1231,"activeCount":84},[1232],{"nctId":1209,"briefTitle":1210,"status":276,"phases":1233,"primaryCompletion":1212,"completion":1213,"start":1214,"enrollment":301,"conditions":1234,"interventions":1235},[76],[15],[1196,1217],{"trials":1237,"activeCount":84},[],{"intervention":1239,"totalTrials":80,"cells":1240},"Paracetamol Codeine",{"EARLY_PHASE1":1241,"PHASE1":1243,"PHASE2":1245,"PHASE3":1247,"PHASE4":1249,"NA":1261},{"trials":1242,"activeCount":84},[],{"trials":1244,"activeCount":84},[],{"trials":1246,"activeCount":84},[],{"trials":1248,"activeCount":84},[],{"trials":1250,"activeCount":84},[1251],{"nctId":1252,"briefTitle":1253,"status":328,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":125,"conditions":1258,"interventions":1260},"NCT03049878","Efficacy of Preoperative Administration of Paracetamol-codeine on Pain Following Impacted Mandibular Third Molar Surgery",[76],"2015-09-20","2016-09-10","2013-02-21",[1259],"To Control Pain After Third Molar Surgery",[1239],{"trials":1262,"activeCount":84},[],{"intervention":1264,"totalTrials":80,"cells":1265},"Rifaximin",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1290},{"trials":1267,"activeCount":84},[],{"trials":1269,"activeCount":84},[],{"trials":1271,"activeCount":84},[],{"trials":1273,"activeCount":84},[],{"trials":1275,"activeCount":84},[1276],{"nctId":1277,"briefTitle":1278,"status":1279,"phases":1280,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":539,"conditions":1284,"interventions":1289},"NCT06630572","Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes","TERMINATED",[76],"2022-04-03","2024-08-01","2021-04-03",[1285,1286,1287,1288],"Liver Cirrhosis","Coagulation Disorder","Platelet Disorder","Endotoxemia",[1264],{"trials":1291,"activeCount":84},[],{"intervention":1293,"totalTrials":80,"cells":1294},"Top-down",{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1301,"PHASE4":1303,"NA":1314},{"trials":1296,"activeCount":84},[],{"trials":1298,"activeCount":84},[],{"trials":1300,"activeCount":84},[],{"trials":1302,"activeCount":84},[],{"trials":1304,"activeCount":84},[1305],{"nctId":1306,"briefTitle":1307,"status":1308,"phases":1309,"primaryCompletion":309,"completion":279,"start":956,"enrollment":84,"conditions":1310,"interventions":1312},"NCT01752790","Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease","WITHDRAWN",[76],[1311],"Pediatric Crohn's Disease",[1293,1313],"Step-up",{"trials":1315,"activeCount":84},[],{"intervention":1313,"totalTrials":80,"cells":1317},{"EARLY_PHASE1":1318,"PHASE1":1320,"PHASE2":1322,"PHASE3":1324,"PHASE4":1326,"NA":1332},{"trials":1319,"activeCount":84},[],{"trials":1321,"activeCount":84},[],{"trials":1323,"activeCount":84},[],{"trials":1325,"activeCount":84},[],{"trials":1327,"activeCount":84},[1328],{"nctId":1306,"briefTitle":1307,"status":1308,"phases":1329,"primaryCompletion":309,"completion":279,"start":956,"enrollment":84,"conditions":1330,"interventions":1331},[76],[1311],[1293,1313],{"trials":1333,"activeCount":84},[],{"intervention":597,"totalTrials":80,"cells":1335},{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1340,"PHASE3":1342,"PHASE4":1344,"NA":1350},{"trials":1337,"activeCount":84},[],{"trials":1339,"activeCount":84},[],{"trials":1341,"activeCount":84},[],{"trials":1343,"activeCount":84},[],{"trials":1345,"activeCount":84},[1346],{"nctId":589,"briefTitle":590,"status":276,"phases":1347,"primaryCompletion":592,"completion":593,"start":594,"enrollment":301,"conditions":1348,"interventions":1349},[76],[346],[597,576],{"trials":1351,"activeCount":84},[],{"intervention":1353,"totalTrials":80,"cells":1354},"Remifentanil",{"EARLY_PHASE1":1355,"PHASE1":1357,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1375},{"trials":1356,"activeCount":84},[],{"trials":1358,"activeCount":84},[],{"trials":1360,"activeCount":84},[],{"trials":1362,"activeCount":84},[],{"trials":1364,"activeCount":84},[1365],{"nctId":1366,"briefTitle":1367,"status":328,"phases":1368,"primaryCompletion":1369,"completion":1369,"start":1370,"enrollment":1371,"conditions":1372,"interventions":1374},"NCT01452880","Remifentanil in Extracorporeal Shock Wave Lithotripsy",[76],"2010-07","2010-01",228,[1373],"Kidney Calculi",[1353,1353],{"trials":1376,"activeCount":84},[],{"intervention":1378,"totalTrials":80,"cells":1379},"Atorvastatin 80mg",{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1386,"PHASE4":1388,"NA":1402},{"trials":1381,"activeCount":84},[],{"trials":1383,"activeCount":84},[],{"trials":1385,"activeCount":84},[],{"trials":1387,"activeCount":84},[],{"trials":1389,"activeCount":84},[1390],{"nctId":1391,"briefTitle":1392,"status":276,"phases":1393,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":562,"conditions":1397,"interventions":1399},"NCT03195153","Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin",[76],"2017-06-23","2017-07-15","2017-03-28",[1398],"Diabetes Mellitus Type 2 Platelets Reactivity Statin",[1378,1400,1401],"ALLOPURINOL 300 MG","Atorvastatin 80mg AND allopurinol 300 mg",{"trials":1403,"activeCount":84},[],{"intervention":1400,"totalTrials":80,"cells":1405},{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1414,"NA":1420},{"trials":1407,"activeCount":84},[],{"trials":1409,"activeCount":84},[],{"trials":1411,"activeCount":84},[],{"trials":1413,"activeCount":84},[],{"trials":1415,"activeCount":84},[1416],{"nctId":1391,"briefTitle":1392,"status":276,"phases":1417,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":562,"conditions":1418,"interventions":1419},[76],[1398],[1378,1400,1401],{"trials":1421,"activeCount":84},[],{"intervention":1401,"totalTrials":80,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1438},{"trials":1425,"activeCount":84},[],{"trials":1427,"activeCount":84},[],{"trials":1429,"activeCount":84},[],{"trials":1431,"activeCount":84},[],{"trials":1433,"activeCount":84},[1434],{"nctId":1391,"briefTitle":1392,"status":276,"phases":1435,"primaryCompletion":1394,"completion":1395,"start":1396,"enrollment":562,"conditions":1436,"interventions":1437},[76],[1398],[1378,1400,1401],{"trials":1439,"activeCount":84},[],{"intervention":1441,"totalTrials":80,"cells":1442},"standard saline",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1460},{"trials":1444,"activeCount":84},[],{"trials":1446,"activeCount":84},[],{"trials":1448,"activeCount":84},[],{"trials":1450,"activeCount":84},[],{"trials":1452,"activeCount":84},[1453],{"nctId":1454,"briefTitle":1455,"status":276,"phases":1456,"primaryCompletion":385,"completion":424,"start":884,"enrollment":301,"conditions":1457,"interventions":1458},"NCT01690832","Fenoldopam for Prevention of Acute Kidney Injury",[76],[15],[1441,1459],"fenoldopam",{"trials":1461,"activeCount":84},[],{"intervention":1459,"totalTrials":80,"cells":1463},{"EARLY_PHASE1":1464,"PHASE1":1466,"PHASE2":1468,"PHASE3":1470,"PHASE4":1472,"NA":1478},{"trials":1465,"activeCount":84},[],{"trials":1467,"activeCount":84},[],{"trials":1469,"activeCount":84},[],{"trials":1471,"activeCount":84},[],{"trials":1473,"activeCount":84},[1474],{"nctId":1454,"briefTitle":1455,"status":276,"phases":1475,"primaryCompletion":385,"completion":424,"start":884,"enrollment":301,"conditions":1476,"interventions":1477},[76],[15],[1441,1459],{"trials":1479,"activeCount":84},[],{"intervention":436,"totalTrials":80,"cells":1481},{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1488,"PHASE4":1490,"NA":1496},{"trials":1483,"activeCount":84},[],{"trials":1485,"activeCount":84},[],{"trials":1487,"activeCount":84},[],{"trials":1489,"activeCount":84},[],{"trials":1491,"activeCount":84},[1492],{"nctId":429,"briefTitle":430,"status":276,"phases":1493,"primaryCompletion":432,"completion":432,"start":433,"enrollment":301,"conditions":1494,"interventions":1495},[76],[15],[408,436],{"trials":1497,"activeCount":84},[],{"intervention":1499,"totalTrials":80,"cells":1500},"Urokinase",{"EARLY_PHASE1":1501,"PHASE1":1503,"PHASE2":1505,"PHASE3":1507,"PHASE4":1509,"NA":1519},{"trials":1502,"activeCount":84},[],{"trials":1504,"activeCount":84},[],{"trials":1506,"activeCount":84},[],{"trials":1508,"activeCount":84},[],{"trials":1510,"activeCount":84},[1511],{"nctId":1512,"briefTitle":1513,"status":276,"phases":1514,"primaryCompletion":593,"completion":1515,"start":309,"enrollment":301,"conditions":1516,"interventions":1517},"NCT01568931","Local Thrombolytics Before Thrombectomy in STEMI",[76],"2021-03",[15],[1499,1518],"Saline",{"trials":1520,"activeCount":84},[],{"intervention":1518,"totalTrials":80,"cells":1522},{"EARLY_PHASE1":1523,"PHASE1":1525,"PHASE2":1527,"PHASE3":1529,"PHASE4":1531,"NA":1537},{"trials":1524,"activeCount":84},[],{"trials":1526,"activeCount":84},[],{"trials":1528,"activeCount":84},[],{"trials":1530,"activeCount":84},[],{"trials":1532,"activeCount":84},[1533],{"nctId":1512,"briefTitle":1513,"status":276,"phases":1534,"primaryCompletion":593,"completion":1515,"start":309,"enrollment":301,"conditions":1535,"interventions":1536},[76],[15],[1499,1518],{"trials":1538,"activeCount":84},[],{"intervention":1540,"totalTrials":80,"cells":1541},"Vitamin C",{"EARLY_PHASE1":1542,"PHASE1":1544,"PHASE2":1546,"PHASE3":1548,"PHASE4":1550,"NA":1562},{"trials":1543,"activeCount":84},[],{"trials":1545,"activeCount":84},[],{"trials":1547,"activeCount":84},[],{"trials":1549,"activeCount":84},[],{"trials":1551,"activeCount":84},[1552],{"nctId":1553,"briefTitle":1554,"status":276,"phases":1555,"primaryCompletion":1556,"completion":1557,"start":331,"enrollment":1558,"conditions":1559,"interventions":1561},"NCT01090895","Treatment of Reperfusion Event by Vitamin C Infusion",[76],"2017-10","2018-12",80,[1560],"Angina Pectoris",[1540],{"trials":1563,"activeCount":84},[],{"intervention":1565,"totalTrials":80,"cells":1566},"Sildenafil",{"EARLY_PHASE1":1567,"PHASE1":1569,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1588},{"trials":1568,"activeCount":84},[],{"trials":1570,"activeCount":84},[],{"trials":1572,"activeCount":84},[],{"trials":1574,"activeCount":84},[],{"trials":1576,"activeCount":84},[1577],{"nctId":1578,"briefTitle":1579,"status":328,"phases":1580,"primaryCompletion":374,"completion":1581,"start":1582,"enrollment":1583,"conditions":1584,"interventions":1587},"NCT00692237","Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes",[76],"2009-12","2008-01",59,[1585,1586],"Diabetes Mellitus, Type 2","Endothelial Dysfunction",[1565],{"trials":1589,"activeCount":84},[],{"intervention":1591,"totalTrials":80,"cells":1592},"Third generation fluoroquinolone",{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1599,"PHASE4":1601,"NA":1611},{"trials":1594,"activeCount":84},[],{"trials":1596,"activeCount":84},[],{"trials":1598,"activeCount":84},[],{"trials":1600,"activeCount":84},[],{"trials":1602,"activeCount":84},[1603],{"nctId":1604,"briefTitle":1605,"status":328,"phases":1606,"primaryCompletion":956,"completion":569,"start":433,"enrollment":1607,"conditions":1608,"interventions":1610},"NCT02130713","Treatment of Chronic Bacterial Prostatitis",[76],210,[1609],"Chronic Bacterial Prostatitis",[1591],{"trials":1612,"activeCount":84},[],{"intervention":1614,"totalTrials":80,"cells":1615},"Testosterone",{"EARLY_PHASE1":1616,"PHASE1":1618,"PHASE2":1620,"PHASE3":1622,"PHASE4":1624,"NA":1637},{"trials":1617,"activeCount":84},[],{"trials":1619,"activeCount":84},[],{"trials":1621,"activeCount":84},[],{"trials":1623,"activeCount":84},[],{"trials":1625,"activeCount":84},[1626],{"nctId":1627,"briefTitle":1628,"status":328,"phases":1629,"primaryCompletion":1630,"completion":1630,"start":1631,"enrollment":1632,"conditions":1633,"interventions":1636},"NCT01123278","Testosterone Replacement in Metabolic Syndrome and Inflammation",[76],"2014-10","2004-01",82,[642,1634,18,1635],"Metabolic Syndrome","Erectile Dysfunction",[1614],{"trials":1638,"activeCount":84},[],{"intervention":312,"totalTrials":80,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1649,"NA":1655},{"trials":1642,"activeCount":84},[],{"trials":1644,"activeCount":84},[],{"trials":1646,"activeCount":84},[],{"trials":1648,"activeCount":84},[],{"trials":1650,"activeCount":84},[1651],{"nctId":305,"briefTitle":306,"status":276,"phases":1652,"primaryCompletion":279,"completion":308,"start":309,"enrollment":301,"conditions":1653,"interventions":1654},[76],[15],[261,312],{"trials":1656,"activeCount":84},[],{"intervention":1658,"totalTrials":80,"cells":1659},"Aspirin, Atorvastatin, Perindopril",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1678},{"trials":1661,"activeCount":84},[],{"trials":1663,"activeCount":84},[],{"trials":1665,"activeCount":84},[],{"trials":1667,"activeCount":84},[],{"trials":1669,"activeCount":84},[1670],{"nctId":1671,"briefTitle":1672,"status":276,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":1675,"enrollment":301,"conditions":1676,"interventions":1677},"NCT04148820","One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease",[76],"2021-10-31","2019-11-01",[426],[1658],{"trials":1679,"activeCount":84},[],{"intervention":1681,"totalTrials":80,"cells":1682},"paracetamol 500 mg plus codeine 30 mg preoperative administration",{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1691,"NA":1703},{"trials":1684,"activeCount":84},[],{"trials":1686,"activeCount":84},[],{"trials":1688,"activeCount":84},[],{"trials":1690,"activeCount":84},[],{"trials":1692,"activeCount":84},[1693],{"nctId":1694,"briefTitle":1695,"status":328,"phases":1696,"primaryCompletion":1697,"completion":1698,"start":1699,"enrollment":530,"conditions":1700,"interventions":1701},"NCT04730297","Comparative Analgesic Effects of Paracetamol\u002FCodeine and Ibuprofen on Pain After Third Molar Surgery",[76],"2020-09-04","2020-10-14","2018-01-01",[1259],[1681,1702],"ibuprofen 400 mg preoperative administration",{"trials":1704,"activeCount":84},[],{"intervention":1702,"totalTrials":80,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1715,"NA":1721},{"trials":1708,"activeCount":84},[],{"trials":1710,"activeCount":84},[],{"trials":1712,"activeCount":84},[],{"trials":1714,"activeCount":84},[],{"trials":1716,"activeCount":84},[1717],{"nctId":1694,"briefTitle":1695,"status":328,"phases":1718,"primaryCompletion":1697,"completion":1698,"start":1699,"enrollment":530,"conditions":1719,"interventions":1720},[76],[1259],[1681,1702],{"trials":1722,"activeCount":84},[],{"intervention":1724,"totalTrials":80,"cells":1725},"Centella",{"EARLY_PHASE1":1726,"PHASE1":1728,"PHASE2":1730,"PHASE3":1732,"PHASE4":1734,"NA":1748},{"trials":1727,"activeCount":84},[],{"trials":1729,"activeCount":84},[],{"trials":1731,"activeCount":84},[],{"trials":1733,"activeCount":84},[],{"trials":1735,"activeCount":84},[1736],{"nctId":1737,"briefTitle":1738,"status":328,"phases":1739,"primaryCompletion":1151,"completion":1151,"start":1151,"enrollment":1740,"conditions":1741,"interventions":1743},"NCT03355846","Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments",[76],99,[1742],"Acute Anal Fissure",[1724,1744,1745,1746,1747],"Proctocella","Flavonil® cps","Flavonil® Cream","Rectalgan Mousse",{"trials":1749,"activeCount":84},[],{"intervention":1744,"totalTrials":80,"cells":1751},{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1760,"NA":1766},{"trials":1753,"activeCount":84},[],{"trials":1755,"activeCount":84},[],{"trials":1757,"activeCount":84},[],{"trials":1759,"activeCount":84},[],{"trials":1761,"activeCount":84},[1762],{"nctId":1737,"briefTitle":1738,"status":328,"phases":1763,"primaryCompletion":1151,"completion":1151,"start":1151,"enrollment":1740,"conditions":1764,"interventions":1765},[76],[1742],[1724,1744,1745,1746,1747],{"trials":1767,"activeCount":84},[],{"intervention":1745,"totalTrials":80,"cells":1769},{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1774,"PHASE3":1776,"PHASE4":1778,"NA":1784},{"trials":1771,"activeCount":84},[],{"trials":1773,"activeCount":84},[],{"trials":1775,"activeCount":84},[],{"trials":1777,"activeCount":84},[],{"trials":1779,"activeCount":84},[1780],{"nctId":1737,"briefTitle":1738,"status":328,"phases":1781,"primaryCompletion":1151,"completion":1151,"start":1151,"enrollment":1740,"conditions":1782,"interventions":1783},[76],[1742],[1724,1744,1745,1746,1747],{"trials":1785,"activeCount":84},[],{"intervention":1746,"totalTrials":80,"cells":1787},{"EARLY_PHASE1":1788,"PHASE1":1790,"PHASE2":1792,"PHASE3":1794,"PHASE4":1796,"NA":1802},{"trials":1789,"activeCount":84},[],{"trials":1791,"activeCount":84},[],{"trials":1793,"activeCount":84},[],{"trials":1795,"activeCount":84},[],{"trials":1797,"activeCount":84},[1798],{"nctId":1737,"briefTitle":1738,"status":328,"phases":1799,"primaryCompletion":1151,"completion":1151,"start":1151,"enrollment":1740,"conditions":1800,"interventions":1801},[76],[1742],[1724,1744,1745,1746,1747],{"trials":1803,"activeCount":84},[],{"intervention":1747,"totalTrials":80,"cells":1805},{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1812,"PHASE4":1814,"NA":1820},{"trials":1807,"activeCount":84},[],{"trials":1809,"activeCount":84},[],{"trials":1811,"activeCount":84},[],{"trials":1813,"activeCount":84},[],{"trials":1815,"activeCount":84},[1816],{"nctId":1737,"briefTitle":1738,"status":328,"phases":1817,"primaryCompletion":1151,"completion":1151,"start":1151,"enrollment":1740,"conditions":1818,"interventions":1819},[76],[1742],[1724,1744,1745,1746,1747],{"trials":1821,"activeCount":84},[],{"intervention":1823,"totalTrials":80,"cells":1824},"biological monitoring",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1829,"PHASE3":1831,"PHASE4":1833,"NA":1845},{"trials":1826,"activeCount":84},[],{"trials":1828,"activeCount":84},[],{"trials":1830,"activeCount":84},[],{"trials":1832,"activeCount":84},[],{"trials":1834,"activeCount":84},[1835],{"nctId":1836,"briefTitle":1837,"status":328,"phases":1838,"primaryCompletion":424,"completion":290,"start":884,"enrollment":1839,"conditions":1840,"interventions":1844},"NCT01807780","Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel",[76],262,[1841,1842,1843],"Vaccination Adverse Events","Vaccination Failure","Specific Antibody Response",[1823],{"trials":1846,"activeCount":84},[],{"intervention":1848,"totalTrials":80,"cells":1849},"Ciprofloxacin",{"EARLY_PHASE1":1850,"PHASE1":1852,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1870},{"trials":1851,"activeCount":84},[],{"trials":1853,"activeCount":84},[],{"trials":1855,"activeCount":84},[],{"trials":1857,"activeCount":84},[],{"trials":1859,"activeCount":84},[1860],{"nctId":1861,"briefTitle":1862,"status":1279,"phases":1863,"primaryCompletion":773,"completion":622,"start":1864,"enrollment":1865,"conditions":1866,"interventions":1868},"NCT01888822","Antibiotic Prophylaxis in Laparoscopic Cholecystectomy",[76],"2013-06",138,[1867],"Cholelithiasis",[1848,1869],"Ampicillin-sulbactam",{"trials":1871,"activeCount":84},[],{"intervention":1869,"totalTrials":80,"cells":1873},{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1888},{"trials":1875,"activeCount":84},[],{"trials":1877,"activeCount":84},[],{"trials":1879,"activeCount":84},[],{"trials":1881,"activeCount":84},[],{"trials":1883,"activeCount":84},[1884],{"nctId":1861,"briefTitle":1862,"status":1279,"phases":1885,"primaryCompletion":773,"completion":622,"start":1864,"enrollment":1865,"conditions":1886,"interventions":1887},[76],[1867],[1848,1869],{"trials":1889,"activeCount":84},[],{"intervention":604,"totalTrials":80,"cells":1891},{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1906},{"trials":1893,"activeCount":84},[],{"trials":1895,"activeCount":84},[],{"trials":1897,"activeCount":84},[],{"trials":1899,"activeCount":84},[],{"trials":1901,"activeCount":84},[1902],{"nctId":599,"briefTitle":600,"status":276,"phases":1903,"primaryCompletion":592,"completion":593,"start":594,"enrollment":301,"conditions":1904,"interventions":1905},[76],[346],[576,604],{"trials":1907,"activeCount":84},[],{"intervention":1909,"totalTrials":80,"cells":1910},"Standard adjuvant systemic chemotherapy",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1917,"PHASE4":1931,"NA":1933},{"trials":1912,"activeCount":84},[],{"trials":1914,"activeCount":84},[],{"trials":1916,"activeCount":84},[],{"trials":1918,"activeCount":84},[1919],{"nctId":1920,"briefTitle":1921,"status":276,"phases":1922,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":1926,"conditions":1927,"interventions":1930},"NCT02974556","Proactive Management of Endoperitoneal Spread in Colonic Cancer",[75],"2024-09-01","2025-09","2024-03-01",140,[1928,1929],"Colon Cancer","Intraperitoneal Rectal Cancer",[1909],{"trials":1932,"activeCount":84},[],{"trials":1934,"activeCount":84},[],{"intervention":380,"totalTrials":80,"cells":1936},{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1943,"PHASE4":1949,"NA":1951},{"trials":1938,"activeCount":84},[],{"trials":1940,"activeCount":84},[],{"trials":1942,"activeCount":84},[],{"trials":1944,"activeCount":84},[1945],{"nctId":371,"briefTitle":372,"status":276,"phases":1946,"primaryCompletion":374,"completion":374,"start":375,"enrollment":252,"conditions":1947,"interventions":1948},[75],[377,378],[380,359],{"trials":1950,"activeCount":84},[],{"trials":1952,"activeCount":84},[],{"intervention":631,"totalTrials":80,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1967,"NA":1969},{"trials":1956,"activeCount":84},[],{"trials":1958,"activeCount":84},[],{"trials":1960,"activeCount":84},[],{"trials":1962,"activeCount":84},[1963],{"nctId":619,"briefTitle":620,"status":328,"phases":1964,"primaryCompletion":622,"completion":623,"start":624,"enrollment":146,"conditions":1965,"interventions":1966},[74,75],[626,627,628,629],[608,631],{"trials":1968,"activeCount":84},[],{"trials":1970,"activeCount":84},[],{"intervention":1972,"totalTrials":80,"cells":1973},"Bivalirudin",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1991,"NA":1993},{"trials":1975,"activeCount":84},[],{"trials":1977,"activeCount":84},[],{"trials":1979,"activeCount":84},[],{"trials":1981,"activeCount":84},[1982],{"nctId":1983,"briefTitle":1984,"status":276,"phases":1985,"primaryCompletion":884,"completion":1986,"start":300,"enrollment":1987,"conditions":1988,"interventions":1989},"NCT01555658","Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis Trial",[75],"2012-10",204,[15],[1972,1990],"Unfractioned Heparin",{"trials":1992,"activeCount":84},[],{"trials":1994,"activeCount":84},[],{"intervention":1990,"totalTrials":80,"cells":1996},{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2009,"NA":2011},{"trials":1998,"activeCount":84},[],{"trials":2000,"activeCount":84},[],{"trials":2002,"activeCount":84},[],{"trials":2004,"activeCount":84},[2005],{"nctId":1983,"briefTitle":1984,"status":276,"phases":2006,"primaryCompletion":884,"completion":1986,"start":300,"enrollment":1987,"conditions":2007,"interventions":2008},[75],[15],[1972,1990],{"trials":2010,"activeCount":84},[],{"trials":2012,"activeCount":84},[],{"intervention":2014,"totalTrials":80,"cells":2015},"continuous infusion of terlipressin",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2020,"PHASE3":2022,"PHASE4":2035,"NA":2037},{"trials":2017,"activeCount":84},[],{"trials":2019,"activeCount":84},[],{"trials":2021,"activeCount":84},[],{"trials":2023,"activeCount":84},[2024],{"nctId":2025,"briefTitle":2026,"status":328,"phases":2027,"primaryCompletion":2028,"completion":2028,"start":2029,"enrollment":252,"conditions":2030,"interventions":2032},"NCT00995839","Terlipressin in Septic Shock: Effects on Microcirculation",[74,75],"2010-02","2008-11",[21,2031],"Sepsis",[2014,2033,2034],"Arginine vasopressin","terlipressin bolus administration",{"trials":2036,"activeCount":84},[],{"trials":2038,"activeCount":84},[],{"intervention":2033,"totalTrials":80,"cells":2040},{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2047,"PHASE4":2053,"NA":2055},{"trials":2042,"activeCount":84},[],{"trials":2044,"activeCount":84},[],{"trials":2046,"activeCount":84},[],{"trials":2048,"activeCount":84},[2049],{"nctId":2025,"briefTitle":2026,"status":328,"phases":2050,"primaryCompletion":2028,"completion":2028,"start":2029,"enrollment":252,"conditions":2051,"interventions":2052},[74,75],[21,2031],[2014,2033,2034],{"trials":2054,"activeCount":84},[],{"trials":2056,"activeCount":84},[],{"intervention":2034,"totalTrials":80,"cells":2058},{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2071,"NA":2073},{"trials":2060,"activeCount":84},[],{"trials":2062,"activeCount":84},[],{"trials":2064,"activeCount":84},[],{"trials":2066,"activeCount":84},[2067],{"nctId":2025,"briefTitle":2026,"status":328,"phases":2068,"primaryCompletion":2028,"completion":2028,"start":2029,"enrollment":252,"conditions":2069,"interventions":2070},[74,75],[21,2031],[2014,2033,2034],{"trials":2072,"activeCount":84},[],{"trials":2074,"activeCount":84},[],{"intervention":390,"totalTrials":80,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2089,"NA":2091},{"trials":2078,"activeCount":84},[],{"trials":2080,"activeCount":84},[],{"trials":2082,"activeCount":84},[],{"trials":2084,"activeCount":84},[2085],{"nctId":382,"briefTitle":383,"status":328,"phases":2086,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":2087,"interventions":2088},[75],[15],[359,390,391],{"trials":2090,"activeCount":84},[],{"trials":2092,"activeCount":84},[],{"intervention":391,"totalTrials":80,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2101,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":84},[],{"trials":2098,"activeCount":84},[],{"trials":2100,"activeCount":84},[],{"trials":2102,"activeCount":84},[2103],{"nctId":382,"briefTitle":383,"status":328,"phases":2104,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":2105,"interventions":2106},[75],[15],[359,390,391],{"trials":2108,"activeCount":84},[],{"trials":2110,"activeCount":84},[],{"intervention":2112,"totalTrials":80,"cells":2113},"0.4% nitroglycerin ointment",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2131,"NA":2133},{"trials":2115,"activeCount":84},[],{"trials":2117,"activeCount":84},[],{"trials":2119,"activeCount":84},[],{"trials":2121,"activeCount":84},[2122],{"nctId":2123,"briefTitle":2124,"status":328,"phases":2125,"primaryCompletion":330,"completion":2126,"start":1631,"enrollment":462,"conditions":2127,"interventions":2129},"NCT01279551","Topical Application of GTN 0.4% in the Treatment of Anismus Following Stapled Haemorrhoidopexy",[74,75],"2010-12",[2128],"Pain After Stapled Haemorrhoidopexy",[2112,2130],"lidocaine cloridrato 2.5% ointment",{"trials":2132,"activeCount":84},[],{"trials":2134,"activeCount":84},[],{"intervention":2130,"totalTrials":80,"cells":2136},{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2149,"NA":2151},{"trials":2138,"activeCount":84},[],{"trials":2140,"activeCount":84},[],{"trials":2142,"activeCount":84},[],{"trials":2144,"activeCount":84},[2145],{"nctId":2123,"briefTitle":2124,"status":328,"phases":2146,"primaryCompletion":330,"completion":2126,"start":1631,"enrollment":462,"conditions":2147,"interventions":2148},[74,75],[2128],[2112,2130],{"trials":2150,"activeCount":84},[],{"trials":2152,"activeCount":84},[],{"intervention":2154,"totalTrials":80,"cells":2155},"Methylprednisolone Sodium Succinate",{"EARLY_PHASE1":2156,"PHASE1":2158,"PHASE2":2160,"PHASE3":2162,"PHASE4":2175,"NA":2177},{"trials":2157,"activeCount":84},[],{"trials":2159,"activeCount":84},[],{"trials":2161,"activeCount":84},[],{"trials":2163,"activeCount":84},[2164],{"nctId":2165,"briefTitle":2166,"status":276,"phases":2167,"primaryCompletion":2168,"completion":1923,"start":2169,"enrollment":2170,"conditions":2171,"interventions":2173},"NCT03745664","Corticosteroids and Myocardial Injury in CAP (COLOSSEUM TRIAL)",[75],"2023-05-16","2021-01-10",122,[2172],"Community-acquired Pneumonia",[2154,2174],"Saline Solution for",{"trials":2176,"activeCount":84},[],{"trials":2178,"activeCount":84},[],{"intervention":2174,"totalTrials":80,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2185,"PHASE3":2187,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":84},[],{"trials":2184,"activeCount":84},[],{"trials":2186,"activeCount":84},[],{"trials":2188,"activeCount":84},[2189],{"nctId":2165,"briefTitle":2166,"status":276,"phases":2190,"primaryCompletion":2168,"completion":1923,"start":2169,"enrollment":2170,"conditions":2191,"interventions":2192},[75],[2172],[2154,2174],{"trials":2194,"activeCount":84},[],{"trials":2196,"activeCount":84},[],{"intervention":2198,"totalTrials":80,"cells":2199},"Memantine Oral",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2218,"NA":2220},{"trials":2201,"activeCount":84},[],{"trials":2203,"activeCount":84},[],{"trials":2205,"activeCount":84},[],{"trials":2207,"activeCount":84},[2208],{"nctId":2209,"briefTitle":2210,"status":276,"phases":2211,"primaryCompletion":2212,"completion":2213,"start":2214,"enrollment":539,"conditions":2215,"interventions":2217},"NCT05015595","Memantine for Refractory OCD Patients",[75],"2022-10-31","2022-12-31","2021-09-01",[2216],"Obsessive-Compulsive Disorder",[2198],{"trials":2219,"activeCount":84},[],{"trials":2221,"activeCount":84},[],{"intervention":2223,"totalTrials":447,"cells":2224},"Phenylephrine",{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2229,"PHASE3":2248,"PHASE4":2250,"NA":2252},{"trials":2226,"activeCount":84},[],{"trials":2228,"activeCount":84},[],{"trials":2230,"activeCount":84},[2231,2240],{"nctId":2232,"briefTitle":2233,"status":328,"phases":2234,"completion":2235,"start":2236,"enrollment":2237,"conditions":2238,"interventions":2239},"NCT00481442","Phenylephrine Versus Norepinephrine in Septic Shock",[74],"2007-03","2007-01",15,[21],[2223],{"nctId":2241,"briefTitle":2242,"status":328,"phases":2243,"primaryCompletion":2244,"completion":2244,"start":461,"enrollment":125,"conditions":2245,"interventions":2246},"NCT00639015","Phenylephrine in Septic Shock",[74],"2008-06",[21],[2223,2247],"Norepinephrine",{"trials":2249,"activeCount":84},[],{"trials":2251,"activeCount":84},[],{"trials":2253,"activeCount":84},[],{"intervention":2247,"totalTrials":447,"cells":2255},{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2276,"PHASE4":2278,"NA":2280},{"trials":2257,"activeCount":84},[],{"trials":2259,"activeCount":84},[],{"trials":2261,"activeCount":84},[2262,2266],{"nctId":2241,"briefTitle":2242,"status":328,"phases":2263,"primaryCompletion":2244,"completion":2244,"start":461,"enrollment":125,"conditions":2264,"interventions":2265},[74],[21],[2223,2247],{"nctId":2267,"briefTitle":2268,"status":328,"phases":2269,"primaryCompletion":2270,"completion":2270,"start":2236,"enrollment":2271,"conditions":2272,"interventions":2273},"NCT00481572","Continuous Infusion of Terlipressin in Septic Shock",[74],"2007-12",45,[21],[2274,2275,2247],"Terlipressin","Vasopressin",{"trials":2277,"activeCount":84},[],{"trials":2279,"activeCount":84},[],{"trials":2281,"activeCount":84},[],{"intervention":465,"totalTrials":80,"cells":2283},{"EARLY_PHASE1":2284,"PHASE1":2286,"PHASE2":2288,"PHASE3":2294,"PHASE4":2296,"NA":2298},{"trials":2285,"activeCount":84},[],{"trials":2287,"activeCount":84},[],{"trials":2289,"activeCount":84},[2290],{"nctId":456,"briefTitle":457,"status":328,"phases":2291,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":2292,"interventions":2293},[74],[21],[446,465],{"trials":2295,"activeCount":84},[],{"trials":2297,"activeCount":84},[],{"trials":2299,"activeCount":84},[],{"intervention":2301,"totalTrials":80,"cells":2302},"Human protein C concentrate",{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2319,"PHASE4":2321,"NA":2323},{"trials":2304,"activeCount":84},[],{"trials":2306,"activeCount":84},[],{"trials":2308,"activeCount":84},[2309],{"nctId":2310,"briefTitle":2311,"status":328,"phases":2312,"primaryCompletion":2313,"completion":2314,"start":2315,"enrollment":252,"conditions":2316,"interventions":2317},"NCT01411670","Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.",[74],"2015-02","2015-04","2011-01",[2031,21],[2301,2318],"Activated protein C",{"trials":2320,"activeCount":84},[],{"trials":2322,"activeCount":84},[],{"trials":2324,"activeCount":84},[],{"intervention":2318,"totalTrials":80,"cells":2326},{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2337,"PHASE4":2339,"NA":2341},{"trials":2328,"activeCount":84},[],{"trials":2330,"activeCount":84},[],{"trials":2332,"activeCount":84},[2333],{"nctId":2310,"briefTitle":2311,"status":328,"phases":2334,"primaryCompletion":2313,"completion":2314,"start":2315,"enrollment":252,"conditions":2335,"interventions":2336},[74],[2031,21],[2301,2318],{"trials":2338,"activeCount":84},[],{"trials":2340,"activeCount":84},[],{"trials":2342,"activeCount":84},[],{"intervention":2344,"totalTrials":80,"cells":2345},"lattulose and rifaximine",{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2363,"PHASE4":2365,"NA":2367},{"trials":2347,"activeCount":84},[],{"trials":2349,"activeCount":84},[],{"trials":2351,"activeCount":84},[2352],{"nctId":2353,"briefTitle":2354,"status":276,"phases":2355,"primaryCompletion":2356,"completion":2357,"start":2358,"enrollment":2359,"conditions":2360,"interventions":2362},"NCT02931123","A RCT COMPARING LACTULOSE AND RIFAXIMIN ASSOCIATED WITH A VEGETABLE DIET IN THE PREVENTION OF POST-TIPS OVERT HEPATIC ENCEPHALOPATHY",[73,74],"2017-11","2018-11","2015-11",58,[2361],"Cirrhotic Patients Undergoing TIPS Placement",[2344],{"trials":2364,"activeCount":84},[],{"trials":2366,"activeCount":84},[],{"trials":2368,"activeCount":84},[],{"intervention":2274,"totalTrials":80,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2381,"PHASE4":2383,"NA":2385},{"trials":2372,"activeCount":84},[],{"trials":2374,"activeCount":84},[],{"trials":2376,"activeCount":84},[2377],{"nctId":2267,"briefTitle":2268,"status":328,"phases":2378,"primaryCompletion":2270,"completion":2270,"start":2236,"enrollment":2271,"conditions":2379,"interventions":2380},[74],[21],[2274,2275,2247],{"trials":2382,"activeCount":84},[],{"trials":2384,"activeCount":84},[],{"trials":2386,"activeCount":84},[],{"intervention":2275,"totalTrials":80,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2399,"PHASE4":2401,"NA":2403},{"trials":2390,"activeCount":84},[],{"trials":2392,"activeCount":84},[],{"trials":2394,"activeCount":84},[2395],{"nctId":2267,"briefTitle":2268,"status":328,"phases":2396,"primaryCompletion":2270,"completion":2270,"start":2236,"enrollment":2271,"conditions":2397,"interventions":2398},[74],[21],[2274,2275,2247],{"trials":2400,"activeCount":84},[],{"trials":2402,"activeCount":84},[],{"trials":2404,"activeCount":84},[],{"intervention":2406,"totalTrials":80,"cells":2407},"Lansoprazole oral tablets 30 mg",{"EARLY_PHASE1":2408,"PHASE1":2421,"PHASE2":2423,"PHASE3":2425,"PHASE4":2427,"NA":2429},{"trials":2409,"activeCount":84},[2410],{"nctId":2411,"briefTitle":2412,"status":276,"phases":2413,"primaryCompletion":2414,"completion":2415,"start":2416,"enrollment":2271,"conditions":2417,"interventions":2420},"NCT04400136","PPI Therapy Impact on GERD After Sleeve Gastrectomy",[72],"2021-07-01","2022-09-01","2020-07-01",[2418,2419,23],"Gastro Esophageal Reflux","Barrett Esophagus",[2406],{"trials":2422,"activeCount":84},[],{"trials":2424,"activeCount":84},[],{"trials":2426,"activeCount":84},[],{"trials":2428,"activeCount":84},[],{"trials":2430,"activeCount":84},[],{"intervention":2432,"totalTrials":32,"cells":2433},"Aspirin",{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2438,"PHASE3":2440,"PHASE4":2453,"NA":2470},{"trials":2435,"activeCount":84},[],{"trials":2437,"activeCount":84},[],{"trials":2439,"activeCount":84},[],{"trials":2441,"activeCount":84},[2442],{"nctId":2443,"briefTitle":2444,"status":276,"phases":2445,"primaryCompletion":2446,"completion":2447,"start":2448,"enrollment":2449,"conditions":2450,"interventions":2452},"NCT02895113","Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes",[75],"2018-01","2018-09","2017-01",418,[2451],"Diabetes",[2432],{"trials":2454,"activeCount":84},[2455,2462],{"nctId":2456,"briefTitle":2457,"status":276,"phases":2458,"primaryCompletion":2315,"completion":956,"start":2459,"enrollment":1558,"conditions":2460,"interventions":2461},"NCT01250340","Type 2 Diabetes Mellitus and Atherosclerosis",[76],"2010-08",[282],[2432],{"nctId":2463,"briefTitle":2464,"status":328,"phases":2465,"primaryCompletion":2466,"completion":884,"start":2315,"enrollment":301,"conditions":2467,"interventions":2469},"NCT01374698","Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.",[76],"2011-09",[2468],"Coronary Arteriosclerosis",[2432],{"trials":2471,"activeCount":84},[2472],{"nctId":2473,"briefTitle":2474,"status":328,"phases":2475,"primaryCompletion":432,"completion":424,"start":330,"enrollment":2476,"conditions":2477,"interventions":2482},"NCT02630862","Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization",[77],240,[2478,2479,2480,2481],"Carotid Stenosis","Cardiovascular Disease","Atherosclerosis","Stroke",[2432,2483],"aspirin plus dipyridamole",{"intervention":961,"totalTrials":447,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2490,"PHASE3":2492,"PHASE4":2494,"NA":2500},{"trials":2487,"activeCount":84},[],{"trials":2489,"activeCount":84},[],{"trials":2491,"activeCount":84},[],{"trials":2493,"activeCount":84},[],{"trials":2495,"activeCount":84},[2496],{"nctId":952,"briefTitle":953,"status":276,"phases":2497,"primaryCompletion":955,"completion":289,"start":956,"enrollment":957,"conditions":2498,"interventions":2499},[76],[34],[939,960,961,962,963],{"trials":2501,"activeCount":84},[2502],{"nctId":2503,"briefTitle":2504,"status":276,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":2510,"interventions":2514},"NCT04368351","Bacteriotherapy in the Treatment of COVID-19",[],"2020-06-30","2020-07-31","2020-03-01",70,[2511,2512,2513],"COVID","Pneumonia","Diarrhea",[2515,2516],"Azithromycin","hydroxychloroquine",{"intervention":2518,"totalTrials":447,"cells":2519},"Dexmedetomidine",{"EARLY_PHASE1":2520,"PHASE1":2522,"PHASE2":2524,"PHASE3":2526,"PHASE4":2536,"NA":2538},{"trials":2521,"activeCount":84},[],{"trials":2523,"activeCount":84},[],{"trials":2525,"activeCount":84},[],{"trials":2527,"activeCount":84},[2528],{"nctId":2529,"briefTitle":2530,"status":328,"phases":2531,"primaryCompletion":2448,"completion":2532,"start":290,"enrollment":2533,"conditions":2534,"interventions":2535},"NCT02638545","Hemodynamic Effects of Dexmedetomidine in Septic Shock",[75],"2017-02",37,[21],[2518],{"trials":2537,"activeCount":84},[],{"trials":2539,"activeCount":84},[2540],{"nctId":2541,"briefTitle":2542,"status":328,"phases":2543,"primaryCompletion":2544,"completion":2544,"start":2545,"enrollment":2546,"conditions":2547,"interventions":2549},"NCT03723538","Dexmedetomidine Use for Sedation in Patients Submitted to Tracheal Surgery",[],"2018-08-31","2018-02-01",14,[2548],"Postoperative Sedation",[2518],{"intervention":2551,"totalTrials":80,"cells":2552},"Hyaluronic Acid",{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2561,"NA":2563},{"trials":2554,"activeCount":84},[],{"trials":2556,"activeCount":84},[],{"trials":2558,"activeCount":84},[],{"trials":2560,"activeCount":84},[],{"trials":2562,"activeCount":84},[],{"trials":2564,"activeCount":84},[2565],{"nctId":2566,"briefTitle":2567,"status":328,"phases":2568,"primaryCompletion":2357,"completion":2357,"start":2569,"enrollment":2570,"conditions":2571,"interventions":2573},"NCT04702334","Hyaluronic Acid for Residual Periodontal Pockets Adjunctive Treatment",[77],"2016-01",144,[2572],"Periodontitis",[2551,2574],"Lidocain",{"intervention":2574,"totalTrials":80,"cells":2576},{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2581,"PHASE3":2583,"PHASE4":2585,"NA":2587},{"trials":2578,"activeCount":84},[],{"trials":2580,"activeCount":84},[],{"trials":2582,"activeCount":84},[],{"trials":2584,"activeCount":84},[],{"trials":2586,"activeCount":84},[],{"trials":2588,"activeCount":84},[2589],{"nctId":2566,"briefTitle":2567,"status":328,"phases":2590,"primaryCompletion":2357,"completion":2357,"start":2569,"enrollment":2570,"conditions":2591,"interventions":2592},[77],[2572],[2551,2574],{"intervention":2594,"totalTrials":80,"cells":2595},"Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam",{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2600,"PHASE3":2602,"PHASE4":2604,"NA":2606},{"trials":2597,"activeCount":84},[],{"trials":2599,"activeCount":84},[],{"trials":2601,"activeCount":84},[],{"trials":2603,"activeCount":84},[],{"trials":2605,"activeCount":84},[],{"trials":2607,"activeCount":84},[2608],{"nctId":2609,"briefTitle":2610,"status":276,"phases":2611,"start":2612,"enrollment":2613,"conditions":2614,"interventions":2619},"NCT00507195","Postanesthesia Cognitive Recovery and Neuropsychologic Complications",[],"2007-05",1200,[2615,2616,2617,2618],"Anesthesia Recovery Period","Delirium, Dementia, Cognitive Disorders","Neurobehavioural Manifestation","Mental Competency",[2594],{"intervention":2621,"totalTrials":80,"cells":2622},"Amoxicillin-Potassium Clavulanate Combination",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2629,"PHASE4":2631,"NA":2633},{"trials":2624,"activeCount":84},[],{"trials":2626,"activeCount":84},[],{"trials":2628,"activeCount":84},[],{"trials":2630,"activeCount":84},[],{"trials":2632,"activeCount":84},[],{"trials":2634,"activeCount":84},[2635],{"nctId":2636,"briefTitle":2637,"status":276,"phases":2638,"primaryCompletion":638,"completion":2639,"start":690,"enrollment":2640,"conditions":2641,"interventions":2643},"NCT01860300","Efficacy of Amoxicilline\u002FClavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus",[77],"2017-05",46,[2642],"Tic Disorders",[2621],{"intervention":2645,"totalTrials":80,"cells":2646},"botulinum toxin A",{"EARLY_PHASE1":2647,"PHASE1":2649,"PHASE2":2651,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2648,"activeCount":84},[],{"trials":2650,"activeCount":84},[],{"trials":2652,"activeCount":84},[],{"trials":2654,"activeCount":84},[],{"trials":2656,"activeCount":84},[],{"trials":2658,"activeCount":84},[2659],{"nctId":2660,"briefTitle":2661,"status":276,"phases":2662,"primaryCompletion":2663,"completion":2664,"start":2665,"enrollment":2666,"conditions":2667,"interventions":2669},"NCT04560101","Motor and Non-motor Symptoms in Cervical Dystonia",[],"2021-02","2021-06","2020-08-01",43,[2668],"Dystonia, Focal",[2645],{"intervention":2671,"totalTrials":80,"cells":2672},"QuantiFERON-TB Gold In-Tube",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2679,"PHASE4":2681,"NA":2683},{"trials":2674,"activeCount":84},[],{"trials":2676,"activeCount":84},[],{"trials":2678,"activeCount":84},[],{"trials":2680,"activeCount":84},[],{"trials":2682,"activeCount":84},[],{"trials":2684,"activeCount":84},[2685],{"nctId":2686,"briefTitle":2687,"status":328,"phases":2688,"primaryCompletion":2028,"completion":2689,"start":2690,"enrollment":2691,"conditions":2692,"interventions":2694},"NCT01475409","A Study on Changes in IFN-gamma Levels Following Anti-TNF Treatment in Patients Undergoing Serial QuantiFERON-TB Gold In-Tube",[77],"2011-02","2008-07",119,[2693],"Inflammatory Rheumatic Diseases",[2671],{"intervention":2696,"totalTrials":80,"cells":2697},"superior laryngeal nerve block with lidocaine",{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2702,"PHASE3":2704,"PHASE4":2706,"NA":2708},{"trials":2699,"activeCount":84},[],{"trials":2701,"activeCount":84},[],{"trials":2703,"activeCount":84},[],{"trials":2705,"activeCount":84},[],{"trials":2707,"activeCount":84},[],{"trials":2709,"activeCount":84},[2710],{"nctId":2711,"briefTitle":2712,"status":276,"phases":2713,"primaryCompletion":2714,"completion":2715,"start":2716,"enrollment":462,"conditions":2717,"interventions":2719},"NCT03586323","Awake Fiber Optic Intubation (AFOI) and Laryngeal Nervous Block",[77],"2018-07-24","2018-08-01","2018-04-15",[2718],"Airway Complication of Anesthesia",[2696],{"intervention":2721,"totalTrials":80,"cells":2722},"Atazanavir",{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2729,"PHASE4":2731,"NA":2733},{"trials":2724,"activeCount":84},[],{"trials":2726,"activeCount":84},[],{"trials":2728,"activeCount":84},[],{"trials":2730,"activeCount":84},[],{"trials":2732,"activeCount":84},[],{"trials":2734,"activeCount":84},[2735],{"nctId":2736,"briefTitle":2737,"status":276,"phases":2738,"primaryCompletion":299,"completion":398,"start":2739,"enrollment":2740,"conditions":2741,"interventions":2743},"NCT02102048","ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir",[77],"2009-01",300,[2742],"HIV",[2721],{"intervention":2745,"totalTrials":80,"cells":2746},"rFSH + r-LH in combination",{"EARLY_PHASE1":2747,"PHASE1":2749,"PHASE2":2751,"PHASE3":2753,"PHASE4":2755,"NA":2757},{"trials":2748,"activeCount":84},[],{"trials":2750,"activeCount":84},[],{"trials":2752,"activeCount":84},[],{"trials":2754,"activeCount":84},[],{"trials":2756,"activeCount":84},[],{"trials":2758,"activeCount":84},[2759],{"nctId":2760,"briefTitle":2761,"status":328,"phases":2762,"primaryCompletion":639,"completion":639,"start":2569,"enrollment":252,"conditions":2763,"interventions":2766},"NCT03204253","Effects of Recombinant LH in Patients With Repeated Implantation Failure",[77],[2764,2765],"Female Infertility","Female Subfertility",[2745,2767],"rFSH alone",{"intervention":2767,"totalTrials":80,"cells":2769},{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2776,"PHASE4":2778,"NA":2780},{"trials":2771,"activeCount":84},[],{"trials":2773,"activeCount":84},[],{"trials":2775,"activeCount":84},[],{"trials":2777,"activeCount":84},[],{"trials":2779,"activeCount":84},[],{"trials":2781,"activeCount":84},[2782],{"nctId":2760,"briefTitle":2761,"status":328,"phases":2783,"primaryCompletion":639,"completion":639,"start":2569,"enrollment":252,"conditions":2784,"interventions":2785},[77],[2764,2765],[2745,2767],{"intervention":2787,"totalTrials":80,"cells":2788},"Vaccine anti-Covid19",{"EARLY_PHASE1":2789,"PHASE1":2791,"PHASE2":2793,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2790,"activeCount":84},[],{"trials":2792,"activeCount":84},[],{"trials":2794,"activeCount":84},[],{"trials":2796,"activeCount":84},[],{"trials":2798,"activeCount":84},[],{"trials":2800,"activeCount":84},[2801],{"nctId":2802,"briefTitle":2803,"status":276,"phases":2804,"primaryCompletion":2805,"completion":2806,"start":2807,"enrollment":2808,"conditions":2809,"interventions":2812},"NCT04844632","COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring",[],"2022-04-01","2022-05-21","2021-02-11",5000,[2810,2811],"Health Care Utilization","Health Care Associated Infection",[2787],{"intervention":2814,"totalTrials":80,"cells":2815},"Nimesulide Ratiopharm® and Flexiban®",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2817,"activeCount":84},[],{"trials":2819,"activeCount":84},[],{"trials":2821,"activeCount":84},[],{"trials":2823,"activeCount":84},[],{"trials":2825,"activeCount":84},[],{"trials":2827,"activeCount":84},[2828],{"nctId":2829,"briefTitle":2830,"status":328,"phases":2831,"primaryCompletion":773,"completion":2532,"start":290,"enrollment":2832,"conditions":2833,"interventions":2835},"NCT03119324","Low Level Laser Therapy in the Treatment of Temporomandibular Joint Disorders (TMJDs) Related Pain",[77],90,[2834],"Temporomandibular Joint Disorders",[2814],{"intervention":2837,"totalTrials":80,"cells":2838},"Rimegepant 75 milligrams",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2845,"PHASE4":2847,"NA":2849},{"trials":2840,"activeCount":84},[],{"trials":2842,"activeCount":84},[],{"trials":2844,"activeCount":84},[],{"trials":2846,"activeCount":84},[],{"trials":2848,"activeCount":84},[],{"trials":2850,"activeCount":84},[2851],{"nctId":2852,"briefTitle":2853,"status":276,"phases":2854,"primaryCompletion":2855,"completion":2856,"start":2857,"enrollment":539,"conditions":2858,"interventions":2860},"NCT05888766","Predict the Response to Acute Treatment of Migraine With Rimegepant 75 mg",[],"2024-07-30","2024-09-30","2023-07-01",[2859],"Migraine Disorders",[2837],{"intervention":2483,"totalTrials":80,"cells":2862},{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2864,"activeCount":84},[],{"trials":2866,"activeCount":84},[],{"trials":2868,"activeCount":84},[],{"trials":2870,"activeCount":84},[],{"trials":2872,"activeCount":84},[],{"trials":2874,"activeCount":84},[2875],{"nctId":2473,"briefTitle":2474,"status":328,"phases":2876,"primaryCompletion":432,"completion":424,"start":330,"enrollment":2476,"conditions":2877,"interventions":2878},[77],[2478,2479,2480,2481],[2432,2483],{"intervention":2880,"totalTrials":80,"cells":2881},"low-molecular-weight heparin",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2886,"PHASE3":2888,"PHASE4":2890,"NA":2892},{"trials":2883,"activeCount":84},[],{"trials":2885,"activeCount":84},[],{"trials":2887,"activeCount":84},[],{"trials":2889,"activeCount":84},[],{"trials":2891,"activeCount":84},[],{"trials":2893,"activeCount":84},[2894],{"nctId":2895,"briefTitle":2896,"status":276,"phases":2897,"primaryCompletion":308,"completion":2446,"start":2313,"enrollment":169,"conditions":2898,"interventions":2901},"NCT03157843","Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards",[],[2899,2900],"Venous Thromboembolism","Deep Venous Thrombosis",[2880],{"intervention":2903,"totalTrials":80,"cells":2904},"Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban",{"EARLY_PHASE1":2905,"PHASE1":2907,"PHASE2":2909,"PHASE3":2911,"PHASE4":2913,"NA":2915},{"trials":2906,"activeCount":84},[],{"trials":2908,"activeCount":84},[],{"trials":2910,"activeCount":84},[],{"trials":2912,"activeCount":84},[],{"trials":2914,"activeCount":84},[],{"trials":2916,"activeCount":84},[2917],{"nctId":2918,"briefTitle":2919,"status":276,"phases":2920,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":301,"conditions":2924,"interventions":2926},"NCT04151680","Anticoagulation on Demand After Percutaneous Coronary Intervention in High Bleeding Risk Patients",[],"2022-11-30","2023-11-30","2019-12-01",[426,2925],"Atrial Fibrillation",[2903,2927],"Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban",{"intervention":2927,"totalTrials":80,"cells":2929},{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2936,"PHASE4":2938,"NA":2940},{"trials":2931,"activeCount":84},[],{"trials":2933,"activeCount":84},[],{"trials":2935,"activeCount":84},[],{"trials":2937,"activeCount":84},[],{"trials":2939,"activeCount":84},[],{"trials":2941,"activeCount":84},[2942],{"nctId":2918,"briefTitle":2919,"status":276,"phases":2943,"primaryCompletion":2921,"completion":2922,"start":2923,"enrollment":301,"conditions":2944,"interventions":2945},[],[426,2925],[2903,2927],{"intervention":2947,"totalTrials":80,"cells":2948},"endocannabinoid palmitoylethanolamide",{"EARLY_PHASE1":2949,"PHASE1":2951,"PHASE2":2953,"PHASE3":2955,"PHASE4":2957,"NA":2959},{"trials":2950,"activeCount":84},[],{"trials":2952,"activeCount":84},[],{"trials":2954,"activeCount":84},[],{"trials":2956,"activeCount":84},[],{"trials":2958,"activeCount":84},[],{"trials":2960,"activeCount":84},[2961],{"nctId":2962,"briefTitle":2963,"status":328,"phases":2964,"primaryCompletion":289,"completion":279,"start":309,"enrollment":2965,"conditions":2966,"interventions":2968},"NCT02645461","Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS",[77],50,[2967],"Amyotrophic Lateral Sclerosis",[2947,2969],"Riluzole",{"intervention":2969,"totalTrials":80,"cells":2971},{"EARLY_PHASE1":2972,"PHASE1":2974,"PHASE2":2976,"PHASE3":2978,"PHASE4":2980,"NA":2982},{"trials":2973,"activeCount":84},[],{"trials":2975,"activeCount":84},[],{"trials":2977,"activeCount":84},[],{"trials":2979,"activeCount":84},[],{"trials":2981,"activeCount":84},[],{"trials":2983,"activeCount":84},[2984],{"nctId":2962,"briefTitle":2963,"status":328,"phases":2985,"primaryCompletion":289,"completion":279,"start":309,"enrollment":2965,"conditions":2986,"interventions":2987},[77],[2967],[2947,2969],{"intervention":2989,"totalTrials":80,"cells":2990},"Faecal Tagging",{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2995,"PHASE3":2997,"PHASE4":2999,"NA":3001},{"trials":2992,"activeCount":84},[],{"trials":2994,"activeCount":84},[],{"trials":2996,"activeCount":84},[],{"trials":2998,"activeCount":84},[],{"trials":3000,"activeCount":84},[],{"trials":3002,"activeCount":84},[3003],{"nctId":3004,"briefTitle":3005,"status":328,"phases":3006,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":301,"conditions":3009,"interventions":3012},"NCT02371655","Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial",[77],"2016-12-01","2015-10-01",[3010,3011],"Cathartic Colon","Colonic Neoplasms",[2989,3013],"Bowel cleansing",{"intervention":3013,"totalTrials":80,"cells":3015},{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3022,"PHASE4":3024,"NA":3026},{"trials":3017,"activeCount":84},[],{"trials":3019,"activeCount":84},[],{"trials":3021,"activeCount":84},[],{"trials":3023,"activeCount":84},[],{"trials":3025,"activeCount":84},[],{"trials":3027,"activeCount":84},[3028],{"nctId":3004,"briefTitle":3005,"status":328,"phases":3029,"primaryCompletion":3007,"completion":3007,"start":3008,"enrollment":301,"conditions":3030,"interventions":3031},[77],[3010,3011],[2989,3013],{"intervention":3033,"totalTrials":80,"cells":3034},"esmolol",{"EARLY_PHASE1":3035,"PHASE1":3037,"PHASE2":3039,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3036,"activeCount":84},[],{"trials":3038,"activeCount":84},[],{"trials":3040,"activeCount":84},[],{"trials":3042,"activeCount":84},[],{"trials":3044,"activeCount":84},[],{"trials":3046,"activeCount":84},[3047],{"nctId":3048,"briefTitle":3049,"status":328,"phases":3050,"primaryCompletion":432,"completion":432,"start":385,"enrollment":2271,"conditions":3051,"interventions":3053},"NCT02188888","Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients",[],[3052,21],"Tachycardia",[3033],{"intervention":3055,"totalTrials":80,"cells":3056},"Doravirine",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3063,"PHASE4":3065,"NA":3067},{"trials":3058,"activeCount":84},[],{"trials":3060,"activeCount":84},[],{"trials":3062,"activeCount":84},[],{"trials":3064,"activeCount":84},[],{"trials":3066,"activeCount":84},[],{"trials":3068,"activeCount":84},[3069],{"nctId":3070,"briefTitle":3071,"status":276,"phases":3072,"primaryCompletion":3073,"completion":3073,"start":3074,"enrollment":2832,"conditions":3075,"interventions":3076},"NCT05202613","Non-Interventional Observational Retrospective Study to Evaluate Doravirine Based-regimens in HIV Infected Aged Patients (DORAge).",[],"2022-12","2022-01-04",[2742],[3055],{"intervention":2516,"totalTrials":80,"cells":3078},{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3085,"PHASE4":3087,"NA":3089},{"trials":3080,"activeCount":84},[],{"trials":3082,"activeCount":84},[],{"trials":3084,"activeCount":84},[],{"trials":3086,"activeCount":84},[],{"trials":3088,"activeCount":84},[],{"trials":3090,"activeCount":84},[3091],{"nctId":2503,"briefTitle":2504,"status":276,"phases":3092,"primaryCompletion":2506,"completion":2507,"start":2508,"enrollment":2509,"conditions":3093,"interventions":3094},[],[2511,2512,2513],[2515,2516],{"intervention":3096,"totalTrials":80,"cells":3097},"Tenofovir-Emtricitabine plus Lopinavir\u002FRitonavir or Darunavir\u002FRitonavir",{"EARLY_PHASE1":3098,"PHASE1":3100,"PHASE2":3102,"PHASE3":3104,"PHASE4":3106,"NA":3108},{"trials":3099,"activeCount":84},[],{"trials":3101,"activeCount":84},[],{"trials":3103,"activeCount":84},[],{"trials":3105,"activeCount":84},[],{"trials":3107,"activeCount":84},[],{"trials":3109,"activeCount":84},[3110],{"nctId":3111,"briefTitle":3112,"status":276,"phases":3113,"primaryCompletion":299,"completion":424,"start":1037,"enrollment":3114,"conditions":3115,"interventions":3117},"NCT02097381","Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy",[77],10,[3116],"HIV Infection",[3096],{"intervention":3119,"totalTrials":80,"cells":3120},"BNT162b2 mRNA Covid-19 Vaccine",{"EARLY_PHASE1":3121,"PHASE1":3123,"PHASE2":3125,"PHASE3":3127,"PHASE4":3129,"NA":3131},{"trials":3122,"activeCount":84},[],{"trials":3124,"activeCount":84},[],{"trials":3126,"activeCount":84},[],{"trials":3128,"activeCount":84},[],{"trials":3130,"activeCount":84},[],{"trials":3132,"activeCount":84},[3133],{"nctId":3134,"briefTitle":3135,"status":276,"phases":3136,"primaryCompletion":3137,"completion":3138,"start":3139,"enrollment":3140,"conditions":3141,"interventions":3143},"NCT04733807","Antibodies Response to mRNA Vaccine Against Covid-19",[],"2021-07-31","2022-02-01","2021-01-28",600,[3142],"Covid-19",[3119],{"intervention":3145,"totalTrials":80,"cells":3146},"forskolin, rutin and vitamins B1 and B2",{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3153,"PHASE4":3155,"NA":3157},{"trials":3148,"activeCount":84},[],{"trials":3150,"activeCount":84},[],{"trials":3152,"activeCount":84},[],{"trials":3154,"activeCount":84},[],{"trials":3156,"activeCount":84},[],{"trials":3158,"activeCount":84},[3159],{"nctId":3160,"briefTitle":3161,"status":328,"phases":3162,"conditions":3163,"interventions":3165},"NCT01254006","Retinal Nerve Fibres Layers Thickness Study in Glaucomatous Patients",[77],[3164],"Glaucoma",[3145]]